As Glp1r expression was undetectable in tumors and surrounding non-tumorous tissue in GAN DIO-NASH-HCC mice, this rules out any potential intratumor GLP1R-associated effects of semaglutide, rendering it most likely that semaglutide lowered tumor burden by improving whole-body metabolism. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.